Showing 2861-2870 of 7669 results for "".
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnso…
- New Research Shows How Immune Cells Organize Themselves in the Epidermishttps://practicaldermatology.com/news/new-research-shows-how-immune-cells-organize-themselves-in-the-epidermis/2460827/New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. Many people don’t realize that the epidermis is home to immune cells. To bring more clarity to how skin’s immune cells do their jobs, S…
- SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skinhttps://practicaldermatology.com/news/skinsafe-cvs-name-top-25-2021-sunscreen-award-winners-for-sensitive-skin/2460826/SkinSAFE partnered with CVS Pharmacy, through the retailer's "Sensitive-Friendly" program, for the first-ever awards that recognize popular products that are safe for sensitive skin types. The experts at SkinSAFE assessed more than 1,400 facial, body, and kids/baby sunscreens to help make it easy …
- Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis?https://practicaldermatology.com/news/can-blocking-the-function-of-the-ccr6-chemokine-help-treat-psoriasis-and-psoriatic-arthritis/2460825/A novel chemical blocker targeting chemokine proteins may significantly reduce skin and joint inflammation in psoriasis and psoriatic arthritis, according to a study in mice. Chemokines are small molecules with a critical role in the body’s response to inflammation and infection. They help guide t…
- Dermavant Submits NDA for Tapinarof for PsOhttps://practicaldermatology.com/news/dermavant-submits-nda-for-tapinarof-for-pso/2460820/Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severe plaque psoriasis in adult patients. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and…
- AstraZeneca's Anifrolumab Shows Benefit for Skin, Joint Symptoms of Lupushttps://practicaldermatology.com/news/astrazenecas-anifrolumab-shows-benefit-for-skin-joint-symptoms-of-lupus/2460819/Anifrolumab is consistently associated with improvements in both skin rash and arthritis across three different disease measures in patients with moderate to severe systemic lupus erythematosus (SLE), results of a new post-hoc analysis of pooled data from the TULIP phase 3 clinical trials show. The…
- AADA Statement on Legislative Interference in Health Care for Transgender Patientshttps://practicaldermatology.com/news/aada-statement-on-legislative-interference-in-health-care-for-transgender-patients/2460817/The American Academy of Dermatology Association strongly opposes recent efforts by state legislatures to restrict physicians’ ability to provide care to transgender youths. Legislation such as the bill enacted this spring in Arkansas as well as those proposed in several other states are a dangerous…
- Cosentyx Now Approved for Psoriasis in Children as Young as Sixhttps://practicaldermatology.com/news/cosentyx-now-approved-for-psoriasis-in-children-as-young-as-six/2460815/Cosentyx® (secukinumab) from Novartis is now FDA approved for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the US. Cosent…
- AAD Survey: Americans Are Confused About Sunscreen Usehttps://practicaldermatology.com/news/aad-survey-americans-are-confused-about-sunscreen-use/2460812/Your patients likely need a refresher course on sunscreen application and SPF. This is the main takeaway message of a recent survey of 1,000 U.S. adults by the American Academy of Dermatology. While 80 percent of Americans know they should apply sunscreen every two hours when outdoors, few do it, …
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been administered…